What Are the Saudi SFDA Local Authorized Representative Requirements?

What Are the Saudi SFDA Local Authorized Representative Requirements?

Direct answer: Under the Saudi Food and Drug Authority (SFDA), all medical device manufacturers that are not based in Saudi Arabia must appoint an Authorized Representative (AR) located in Saudi Arabia. The AR serves as the legal contact for communication with the SFDA, must be registered with the SFDA and hold the required compliance qualifications, and is responsible for assisting with product registration, submitting technical files, handling adverse event reports, post-market surveillance, and recalls. The manufacturer and the AR must sign a formal agreement that clearly defines both parties' responsibilities, and the AR must be able to bear joint legal liability arising from product defects. The AR should have a quality management system certification, such as ISO 13485, and be familiar with SFDA registration procedures and regulatory updates. For medical devices imported into Saudi Arabia, manufacturers may not communicate directly with the SFDA; all documents must be submitted through the AR. In addition, the AR must retain product technical files and registration certificates for at least 10 years and cooperate with SFDA on-site inspections. When selecting an AR, manufacturers are advised to prioritize service providers with a physical office in Saudi Arabia, medical device registration experience, and a strong reputation.

Published: July 8, 2026, 09:00; Updated: July 8, 2026, 09:00.

This FAQ addresses the issues companies should prioritize in practical projects involving international medical device registration, dossier preparation, compliance pathways, and post-market maintenance. It is compiled from AIMEILI registration practice materials, the international medical device registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target regulatory authority and the product dossier basis.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Materials and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Viewpoint
• Common Follow-up Questions
• Continue Reading
• Applicable Boundaries

Key Summary

The Saudi Food and Drug Authority (SFDA) requires all non-Saudi medical device manufacturers to appoint an Authorized Representative (AR) within Saudi Arabia. The AR must be registered with the SFDA and have compliant qualifications, and is responsible for assisting with product registration, submitting technical files, handling adverse event reports, post-market surveillance, and recalls. The manufacturer and the AR must sign a formal agreement that clearly defines responsibilities, and the AR must be able to bear joint legal liability arising from product defects. The AR should have a quality management system certification, such as ISO 13485, and be familiar with SFDA registration procedures and regulatory updates. For medical devices imported into Saudi Arabia, manufacturers may not communicate directly with the SFDA; all documents must be submitted through the AR. The AR must retain product technical files and registration certificates for at least 10 years and cooperate with SFDA on-site inspections. When selecting an AR, manufacturers should prioritize service providers with a physical office in Saudi Arabia, medical device registration experience, and a strong reputation.

Applicable Scenarios and Core Questions

Manufacturers are most concerned about whether the AR can efficiently complete SFDA registration, reduce compliance risk, and bear legal liability arising from product issues. In addition, the AR's responsiveness, fee structure, and speed of market access are key considerations. Companies expect the AR to accurately interpret new SFDA rules and avoid registration delays caused by documentation issues.

Registration Decision Logic

First, confirm whether the manufacturer is located outside Saudi Arabia. If so, an AR must be appointed. Next, assess the AR's qualifications: whether it is registered or filed with the SFDA, usually verifiable through the SFDA website; whether it has medical device registration experience; and whether it holds ISO 13485 certification. Then check whether the authorization agreement covers product liability, post-market surveillance, and document retention clauses. Finally, determine the registration pathway according to the product risk class, such as Class A, B, C, or D. The AR must assist with risk classification and technical file submission.

Core Materials and Evidence

• Authorization agreement signed by the manufacturer and the AR, including an Arabic-language version
• AR registration certificate or filing number with the SFDA
• AR business license and proof of business scope
• Technical files provided by the manufacturer, including product labels, instructions for use, and risk management report
• AR quality management system certificate, such as ISO 13485
• Product liability insurance certificate, if applicable

Common Errors

• The AR is not registered with the SFDA, causing documents to be returned
• The authorization agreement does not include product liability clauses or does not comply with Saudi legal requirements
• Use of unofficial or unqualified translations; officially certified translations are required
• The AR fails to update the manufacturer's product changes in a timely manner
• Ignoring the AR's obligation to retain documents for 10 years

Company Preparation Checklist

• Identify candidate AR organizations in Saudi Arabia and evaluate their qualifications
• Draft and sign an authorization agreement that meets SFDA requirements, in Chinese, English, and Arabic
• Prepare complete technical files, including clinical evaluation reports and label samples
• Ensure the AR obtains product liability insurance or provides corresponding evidence
• Establish a communication mechanism with the AR and clarify the adverse event reporting process
• Regularly review the AR's compliance status and ensure certificates remain valid

AIMEILI Regulatory Interpretation and Business Impact

Selecting an AR is a critical starting point for successful Saudi registration. We recommend that manufacturers look beyond price and focus on the AR's professional team and past successful cases. In recent years, the Saudi SFDA has strengthened supervision of ARs; if an AR fails in its duties, it may affect the manufacturer's market access. AIMEILI can assist manufacturers in screening qualified ARs and provide agreement review and document preparation support to reduce communication costs.

Common Follow-up Questions

Q: If we change the Authorized Representative, do we need to notify the SFDA?

A: Yes. A change application must be submitted with the new authorization agreement, and the former representative must ensure that responsibilities are not left unclear during the transition period.

Q: Must the Authorized Representative be a Saudi local company?

A: It must be a legally registered company in Saudi Arabia with independent legal person status.

Continue Reading

• Previous: How long does the Malaysia MDA medical device registration process take?
• Next: How to conduct IVD product registration in Southeast Asia: country selection, dossier preparation, and pathway planning?

Recommended Reading

• What should companies prepare before Australian TGA medical device registration?
• Can CE materials be reused for Singapore HSA medical device registration?
• What core materials are required for UAE MOHAP medical device registration?
• Why is the Brazilian ANVISA medical device registration cycle so long?
• What is the difference between a Vietnam medical device import license and registration certificate?
• How should an Indonesian medical device registration local agent be selected?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI International Medical Device Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicable boundary: This article is intended for preliminary understanding, dossier preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal advice.